UroGen Pharma Ltd

Stock Chart, Company Information, and Scan Results

$26.25(as of May 6, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

UroGen Pharma Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$26.25
Ticker SymbolURGN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees291
CountyUSA
Market Cap$1,161.0M
EBIDTA-124.6M
10-Day Moving Average23.99
P/E Ratio-8.42
20-Day Moving Average23.25
Forward P/E Ratio0.00
50-Day Moving Average20.61
Earnings per Share-3.19
200-Day Moving Average20.60
Profit Margin-69.68%
RSI67.70
Shares Outstanding48.7M
ATR1.57
52-Week High30.00
Volume2,786,549
52-Week Low3.42
Most Recent Support Level22.68
Book Value-105.5M
Most Recent Resistance Level24.42
P/B Ratio-12.25
Upper Keltner26.77
P/S Ratio11.77
Lower Keltner19.72
Debt-to-Equity Ratio26.77
Next Earnings DateUnknown
Cash Surplus64.3M
Next Ex-Dividend DateUnknown

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

UroGen Pharma Ltd In Our Stock Scanner

As of May 07, 2026
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Earnings AnnouncementsScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.